Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02726750 · ClinicalTrials.gov registry record
Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma
A clinical trial of Monoclonal Gammopathy of Undetermined Significance and Smoldering Plasma Cell Myeloma, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- 200
- Enrollment target
- 1
- Study location
NCT02726750 is a study of Monoclonal Gammopathy of Undetermined Significance and Smoldering Plasma Cell Myeloma that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 200 participants, below the 662-participant average among 11 other Monoclonal Gammopathy of Undetermined Significance trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02726750, a study of Monoclonal Gammopathy of Undetermined Significance and Smoldering Plasma Cell Myeloma, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to find markers that may help to predict why some patients who have monoclonal gammopathy of unknown significance (MGUS) or smoldering multiple myeloma (SMM) that have no signs or symptoms of disease (asymptomatic) develop multiple myeloma, while others do not. Studying markers such as age, level of proteins in blood, percent of abnormal blood cells in the bone marrow, genes in the abnormal blood cells, and bone abnormalities may help researchers to validate clinical and genomic predictors for future use in clinical practice.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Laboratory Biomarker Analysis
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2015-12-14 |
| Est. Completion | 2026-04-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02726750
The ClinicalTrials.gov registry entry for NCT02726750 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 662-participant average among 11 other Monoclonal Gammopathy of Undetermined Significance trials with a reported enrollment target (70% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Monoclonal Gammopathy of Undetermined Significance appearing as the primary indexed condition, and to 2 interventions - of which Biospecimen Collection is the first listed.
NCT02726750 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT02726750 about?
NCT02726750 is a clinical study titled "Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma". The goal of this study is to find markers that may help to predict why some patients who have monoclonal gammopathy of unknown significance (MGUS) or smoldering multiple myeloma (SMM) that have no signs or symptoms of disease (asymptomatic) develop multiple myeloma, while others do not. Studying mar...
What is the current status of trial NCT02726750?
This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2015-12-14. Estimated completion is 2026-04-30.
What conditions does trial NCT02726750 study?
This clinical trial studies the following conditions: Monoclonal Gammopathy of Undetermined Significance, Smoldering Plasma Cell Myeloma.
What interventions are being tested in trial NCT02726750?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Laboratory Biomarker Analysis (OTHER).
Who is sponsoring clinical trial NCT02726750?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02726750 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Monoclonal Gammopathy of Undetermined Significance
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
RECRUITING · NA
-
Sleep Apnea in Patients With MGUS and MM
RECRUITING
-
Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
RECRUITING
-
Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer
RECRUITING · Phase 2
-
A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)
RECRUITING · NA
-
Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions
RECRUITING
Explore more on PlainTrial
Monoclonal Gammopathy of Undetermined Significance
All registered trials for this condition
Smoldering Plasma Cell Myeloma
All registered trials for this condition
Texas
All trials with a study site in Texas
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.